Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Bioventus Inc.BVS · Entity 4996 | Fmr. Chief Commercial Officer | April 01, 2022 | April 21, 2023 |
| TELA Bio, Inc.TELA · Entity 7381 | Director | June 01, 2023 | June 02, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Bioventus Inc.
Report date April 01, 2022 · Filed April 21, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 87,250 |
Reported balance
After 2022-04-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-04-01 · Sale · Disposed 40 · Balance 87,250 F1: Reflects shares sold to cover taxes in connection with shares purchased under the Company's 2021 Employee Stock Purchase Plan. F2: Includes an aggregate of 3,398 shares of Class A common stock purchased under the Company's 2021 Employee Stock Purchase Plan. This number has also been adjusted to account for a scrivener's error in a prior filing which attributed an acquisition of 40 shares under the Company's 2021 Employee Stock Purchase Plan. |
| Class A Common StockSEC Table I · non-derivative | Direct | 87,155 |
Reported balance
After 2022-07-01 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2022-07-01 · Sale · Disposed 95 · Balance 87,155 F1: Reflects shares sold to cover taxes in connection with shares purchased under the Company's 2021 Employee Stock Purchase Plan. |
| Class A Common StockSEC Table I · non-derivative | Direct | 87,148 |
Reported balance
After 2022-10-03 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2022-10-03 · Sale · Disposed 7 · Balance 87,148 F1: Reflects shares sold to cover taxes in connection with shares purchased under the Company's 2021 Employee Stock Purchase Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects shares sold to cover taxes in connection with shares purchased under the Company's 2021 Employee Stock Purchase Plan.
F2: Includes an aggregate of 3,398 shares of Class A common stock purchased under the Company's 2021 Employee Stock Purchase Plan. This number has also been adjusted to account for a scrivener's error in a prior filing which attributed an acquisition of 40 shares under the Company's 2021 Employee Stock Purchase Plan.
TELA Bio, Inc.
Report date June 01, 2023 · Filed June 02, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,270 |
Reported balance
After 2023-06-01 transaction · row 1
1 source rowRow 1 · 2023-06-01 · Grant · Acquired 3,135 · Balance 6,270 F1: These restricted stock units vest on the earlier of (a) June 1, 2024, (b) the next annual meeting of stockholders, or (c) the occurrence of a Change in Control (as defined in the Issuer's Amended and Restated 2019 Equity Incentive Plan), in each case subject to the Reporting Person's continued service through the applicable vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.34 · Expires 2033-06-01 | Direct | 5,360 |
Reported balance
After 2023-06-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-06-01 · Grant · Acquired 5,360 · Balance 5,360 F2: The option vests on the earlier of (a) June 1, 2024, (b) the next annual meeting of stockholders, or (c) the occurrence of a Change in Control (as defined in the Issuer's Amended and Restated 2019 Equity Incentive Plan), in each case subject to the Reporting Person's continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: These restricted stock units vest on the earlier of (a) June 1, 2024, (b) the next annual meeting of stockholders, or (c) the occurrence of a Change in Control (as defined in the Issuer's Amended and Restated 2019 Equity Incentive Plan), in each case subject to the Reporting Person's continued service through the applicable vesting date.
F2: The option vests on the earlier of (a) June 1, 2024, (b) the next annual meeting of stockholders, or (c) the occurrence of a Change in Control (as defined in the Issuer's Amended and Restated 2019 Equity Incentive Plan), in each case subject to the Reporting Person's continued service through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 01, 2023 Filed Jun 2, 2023 20:36 UTC | TELA Bio, Inc. TELA · Entity 7381 | GrantStock Option (Right to Buy) · Derivative | 5,360 | $0.00 Strike: $10.34 | $0.00 |
DisclosureSEC source: 0001062993-23-012775 · form4.xml · derivative · entry 2 Nosenzo John · CIK 0001835973 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,360 Underlying: Common Stock · 5,360 shares Expires 2033-06-01 F2 · derivative.exercise_date: The option vests on the earlier of (a) June 1, 2024, (b) the next annual meeting of stockholders, or (c) the occurrence of a Change in Control (as defined in the Issuer's Amended and Restated 2019 Equity Incentive Plan), in each case subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 01, 2023 Filed Jun 2, 2023 20:36 UTC | TELA Bio, Inc. TELA · Entity 7381 | GrantCommon Stock | 3,135 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-012775 · form4.xml · nonDerivative · entry 1 Nosenzo John · CIK 0001835973 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,270 F1 · shares: These restricted stock units vest on the earlier of (a) June 1, 2024, (b) the next annual meeting of stockholders, or (c) the occurrence of a Change in Control (as defined in the Issuer's Amended and Restated 2019 Equity Incentive Plan), in each case subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| October 03, 2022 Filed Apr 21, 2023 21:45 UTC | Bioventus Inc. BVS · Entity 4996 | SaleClass A Common Stock | 7 | $7.00 | $49.00 |
DisclosureSEC source: 0001578563-23-000026 · primary_doc.xml · nonDerivative · entry 3 Nosenzo John · CIK 0001835973 · Fmr. Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 87,148 F1 · kind: Reflects shares sold to cover taxes in connection with shares purchased under the Company's 2021 Employee Stock Purchase Plan. Read SEC document |
| July 01, 2022 Filed Apr 21, 2023 21:45 UTC | Bioventus Inc. BVS · Entity 4996 | SaleClass A Common Stock | 95 | $6.73 | $639.35 |
DisclosureSEC source: 0001578563-23-000026 · primary_doc.xml · nonDerivative · entry 2 Nosenzo John · CIK 0001835973 · Fmr. Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 87,155 F1 · kind: Reflects shares sold to cover taxes in connection with shares purchased under the Company's 2021 Employee Stock Purchase Plan. Read SEC document |
| June 01, 2022 Filed Jun 2, 2022 20:07 UTC | TELA Bio, Inc. TELA · Entity 7381 | GrantStock Option (Right to Buy) · Derivative | 5,360 | $0.00 Strike: $6.84 | $0.00 |
DisclosureSEC source: 0001062993-22-014133 · form4.xml · derivative · entry 2 Nosenzo John · CIK 0001835973 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,360 Underlying: Common Stock · 5,360 shares Expires 2032-06-01 F2 · derivative.exercise_date: The option vests on the earlier of (a) June 1, 2023, (b) the next annual meeting of stockholders, or (c) the occurrence of a Change in Control (as defined in the Issuer's Amended and Restated 2019 Equity Incentive Plan), in each case subject to the Reporting Peron's continued service through the applicable vesting date. Read SEC document |
| June 01, 2022 Filed Jun 2, 2022 20:07 UTC | TELA Bio, Inc. TELA · Entity 7381 | GrantCommon Stock | 3,135 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-014133 · form4.xml · nonDerivative · entry 1 Nosenzo John · CIK 0001835973 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,135 F1 · shares: These restricted stock units vest on the earlier of (a) June 1, 2023, (b) the next annual meeting of stockholders, or (c) the occurrence of a Change in Control (as defined in the Issuer's Amended and Restated 2019 Equity Incentive Plan), in each case subject to the Reporting Peron's continued service through the applicable vesting date. Read SEC document |
| April 04, 2022 Filed Apr 6, 2022 01:14 UTC | Bioventus Inc. BVS · Entity 4996 | SaleClass A Common Stock | 65,963 | $11.12 | $733,501.96 |
DisclosureSEC source: 0000899243-22-013963 · doc4.xml · nonDerivative · entry 2 Nosenzo John · CIK 0001835973 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,932 F3 · kind: Reflects shares sold to cover taxes upon the vesting of RSUs on April 1, 2022 pursuant to a standing 10b5-1 instruction. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.00 to $11.48, inclusive. Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 01, 2022 Filed Apr 6, 2022 01:14 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionRestricted Stock Units · Derivative | 106,485 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-013963 · doc4.xml · derivative · entry 3 Nosenzo John · CIK 0001835973 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 106,485 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: The RSUs vested on April 1, 2022. F5 · derivative.exercise_date: The RSUs vested on April 1, 2022. F5 · derivative.expiration_date: The RSUs vested on April 1, 2022. Read SEC document |
| April 01, 2022 Filed Apr 6, 2022 01:14 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionClass A Common Stock | 106,485 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-013963 · doc4.xml · nonDerivative · entry 1 Nosenzo John · CIK 0001835973 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,895 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F2 · balance_after: Includes 40 shares acquired under the Company's 2021 Employee Stock Purchase Program on April 1, 2022. Read SEC document |
| April 01, 2022 Filed Apr 21, 2023 21:45 UTC | Bioventus Inc. BVS · Entity 4996 | SaleClass A Common Stock | 40 | $14.07 | $562.80 |
DisclosureSEC source: 0001578563-23-000026 · primary_doc.xml · nonDerivative · entry 1 Nosenzo John · CIK 0001835973 · Fmr. Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 87,250 F1 · kind: Reflects shares sold to cover taxes in connection with shares purchased under the Company's 2021 Employee Stock Purchase Plan. F2 · balance_after: Includes an aggregate of 3,398 shares of Class A common stock purchased under the Company's 2021 Employee Stock Purchase Plan. This number has also been adjusted to account for a scrivener's error in a prior filing which attributed an acquisition of 40 shares under the Company's 2021 Employee Stock Purchase Plan. Read SEC document |
| February 14, 2022 Filed Feb 16, 2022 02:17 UTC | Bioventus Inc. BVS · Entity 4996 | SaleClass A Common Stock | 534 | $11.99 | $6,401.33 |
DisclosureSEC source: 0000899243-22-006538 · doc4.xml · nonDerivative · entry 2 Nosenzo John · CIK 0001835973 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,370 F2 · kind: Reflects shares sold to cover taxes upon the vesting of restricted stock units on February 11, 2022 pursuant to a standing 10b5-1 instruction. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.87 to $11.99, inclusive. Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 11, 2022 Filed Feb 16, 2022 02:17 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionRestricted Stock Units · Derivative | 1,470 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-006538 · doc4.xml · derivative · entry 3 Nosenzo John · CIK 0001835973 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 1,470 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Class A common stock. F4 · derivative.exercise_date: The restricted stock units vested on February 11, 2022. F4 · derivative.expiration_date: The restricted stock units vested on February 11, 2022. Read SEC document |
| February 11, 2022 Filed Feb 16, 2022 02:17 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionClass A Common Stock | 1,470 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-006538 · doc4.xml · nonDerivative · entry 1 Nosenzo John · CIK 0001835973 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,904 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Class A common stock. Read SEC document |
| February 10, 2022 Filed Feb 15, 2022 01:41 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionPhantom Profit Units · Derivative | 66,139 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-006332 · doc4.xml · derivative · entry 3 Nosenzo John · CIK 0001835973 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 66,139 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Phantom Profit Unit represented a contingent right to receive one share of Class A common stock and vested on the one-year anniversary of the consummation of the Isuser's initial public offering. F1 · derivative.exercise_date: Each Phantom Profit Unit represented a contingent right to receive one share of Class A common stock and vested on the one-year anniversary of the consummation of the Isuser's initial public offering. F1 · derivative.expiration_date: Each Phantom Profit Unit represented a contingent right to receive one share of Class A common stock and vested on the one-year anniversary of the consummation of the Isuser's initial public offering. Read SEC document |
| February 10, 2022 Filed Feb 15, 2022 01:41 UTC | Bioventus Inc. BVS · Entity 4996 | Tax withholdingClass A Common Stock | 24,205 | $12.88 | $311,760.40 |
DisclosureSEC source: 0000899243-22-006332 · doc4.xml · nonDerivative · entry 2 Nosenzo John · CIK 0001835973 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,434 Read SEC document |
| February 10, 2022 Filed Feb 15, 2022 01:41 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionClass A Common Stock | 66,139 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-006332 · doc4.xml · nonDerivative · entry 1 Nosenzo John · CIK 0001835973 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,639 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Phantom Profit Unit represented a contingent right to receive one share of Class A common stock and vested on the one-year anniversary of the consummation of the Isuser's initial public offering. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 21:08 UTC | TELA Bio, Inc. TELA · Entity 7381 | GrantStock Option (Right to Buy) · Derivative | 8,000 | $0.00 Strike: $13.16 | $0.00 |
DisclosureSEC source: 0001192482-21-000493 · edgar.xml · derivative · entry 1 Nosenzo John · CIK 0001835973 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2031-06-02 F1 · derivative.exercise_date: The option vests in 36 equal monthly installments on the second day of each of the 36 calendar months immediately following June 2, 2021, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 20:31 UTC | Bioventus Inc. BVS · Entity 4996 | GrantRestricted Stock Units · Derivative | 106,485 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-014832 · doc4.xml · derivative · entry 2 Nosenzo John · CIK 0001835973 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,485 Underlying: Class A Common Stock · 106,485 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The restricted stock units vest on April 1, 2022 and have no expiration date. F2 · derivative.expiration_date: The restricted stock units vest on April 1, 2022 and have no expiration date. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 23:14 UTC | Bioventus Inc. BVS · Entity 4996 | GrantRestricted Stock Units · Derivative | 1,470 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-006750 · doc4.xml · derivative · entry 1 Nosenzo John · CIK 0001835973 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,470 Underlying: Class A Common Stock · 1,470 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The restricted stock units vest on February 11, 2022. F2 · derivative.expiration_date: The restricted stock units vest on February 11, 2022. Read SEC document |
| February 11, 2021 Filed Apr 5, 2021 20:31 UTC | Bioventus Inc. BVS · Entity 4996 | PurchaseCommon Stock | 500 | $13.00 | $6,500.00 |
DisclosureSEC source: 0000899243-21-014832 · doc4.xml · nonDerivative · entry 1 Nosenzo John · CIK 0001835973 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.